Phaseline

Companies › Rokote Laboratories Finland Oy

Rokote Laboratories Finland Oy: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
COV2 vaccine formulation A
Serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein
–Phase 1COVID - 19Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07416539COV2 vaccine formulation APhase 1COVID - 19Infectious diseaseNov 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.